About capricor therapeutics - CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
CAPR At a Glance
Capricor Therapeutics, Inc.
10865 Road to the Cure
San Diego, California 92121
| Phone | 1-858-727-1755 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -105,043,946.00 | |
| Sector | Health Technology | Employees | 231 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CAPR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.415 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.799 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.017 |
CAPR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -454,735.697 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CAPR Liquidity
| Current Ratio | 9.011 |
| Quick Ratio | 9.011 |
| Cash Ratio | 8.877 |
CAPR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -39.607 |
| Return on Equity | -46.556 |
| Return on Total Capital | -32.447 |
| Return on Invested Capital | -44.741 |
CAPR Capital Structure
| Total Debt to Total Equity | 5.868 |
| Total Debt to Total Capital | 5.543 |
| Total Debt to Total Assets | 4.985 |
| Long-Term Debt to Equity | 4.683 |
| Long-Term Debt to Total Capital | 4.423 |